Come have a 🍺 or ☕️ and join @ajperissinotti, @Berninini, and special guest Dr. Luke Fletcher @LFletcherMD15 in our discussion of innovations and best practices in community hematology! https://t.co/vu5U3k3ZYd
@AaronGoodman33 The tables a littl wonky. States iron defiicency ferritin <30 but ida is ferritin <12. Definitely 30 for both, seen tons of consults for anemia and patient told iron is ok cause ferritin is 15 and after iron replacement counts totally normal
@AaronGoodman33 Not that this ever becomes approved, but think for a second how much of a nightmare this would be trying to obtain and patients take a regimen like this outside of a trial? 4 oral drugs, yikes
4/ 📽️ How will emerging agents change #myelofibrosis treatment❓ What AEs can be expected w/ emerging therapies❓
@AaronGerds will tell you all about it in the video below❗️
#MFBrief
https://t.co/onKwKgdhbt
2/ How do you manage anemia in patients w/ #myelofibrosis & will your approach change w/ approval of MMB❓ #MFBrief
✍️ Agents w/ spleen, symptom, & anemia benefit
Luspatercept: ⬆️ TI & durable response
Momelotinib: ⬆️ TI & ⬇️ anemia
Pacritinib: ⬆️ TI
@SoMeCME This is exactly type of patient I would consider switching. Ruxolitinib at 5mg BID does not have good efficacy for treating myelofibrosis (mainly just mild anti-inflammatory effect)
6/ We hope you enjoyed this #myelofibrosis education❗️
Complete the posttest & evaluation here 👉🏼 https://t.co/jr6NozsYkt
& claim your 🆓 CME❗️
If you missed #MFBrief1 ��🏼 https://t.co/yzgKlycyDQ
If you missed #MFBrief2 👉🏼 https://t.co/lokpGcJscX
@TalhaBadarMD@SoMeCME Important point, use what you have and can get, but push to get best risk stratification you can. Also, can refine as information comes in as well.
5/ 📊 What DIPSS risk group would you assign to a 75 yo patient w/ myelofibrosis, unintentional weight loss, fever/night sweats, anemia (Hgb 8.8 g/dL), adequate platelets (211 K/μL), & 2% circulating blasts❓
#MFBrief